$
2.100
-0.06(-2.778%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.230
Open
2.160
VWAP
2.16
Vol
151.61K
Mkt Cap
171.49M
Low
2.100
Amount
327.66K
EV/EBITDA(TTM)
--
Total Shares
80.88M
EV
2.86M
EV/OCF(TTM)
--
P/S(TTM)
--
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Show More
3 Analyst Rating
up Image
170.00% Upside
Wall Street analysts forecast IMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAB is 5.67 USD with a low forecast of 5.00 USD and a high forecast of 7.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
170.00% Upside
Current: 2.100
sliders
Low
5.00
Averages
5.67
High
7.00
Lucid Capital
initiated
$5
2025-05-28
Reason
Lucid Capital initiated coverage of I-Mab with a Buy rating and $5 price target. I-Mab is a clinical-stage biotechnology company focused on precision therapeutics for the treatment of cancer, the analyst tells investors in a research note. The firm believes the company's CLDN18.2 x 4-1BB bispecific antibody, givastomig, could be a significant value driver for shares, approaching the top-line Phase 1b combination dose escalation and dose expansion data.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Maintains
$8 → $7
2025-04-04
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$4
2025-04-04
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$8
2024-11-15
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$8
2024-09-17
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$8
2024-08-29
Reason

Valuation Metrics

The current forward P/E ratio for I-Mab (IMAB.O) is -10.29, compared to its 5-year average forward P/E of -18.86. For a more detailed relative valuation and DCF analysis to assess I-Mab 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.86
Current PE
-10.29
Overvalued PE
10.15
Undervalued PE
-47.88

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
71.11
Undervalued EV/EBITDA
-60.30

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.55
Current PS
0.00
Overvalued PS
49.87
Undervalued PS
-20.77

Financials

Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
-38.07%
-5.27M
Operating Profit
FY2025Q1
YoY :
-66.56%
-3.15M
Net Income after Tax
FY2025Q1
YoY :
-77.78%
-0.02
EPS - Diluted
FY2020Q4
YoY :
-581.77%
152.96M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.0
Volume
1
6-9
Months
928.6K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

IMAB News & Events

Events Timeline

2025-07-17 (ET)
2025-07-17
07:05:24
I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech
select
2025-07-02 (ET)
2025-07-02
11:20:43
I-Mab presents Gibastomig Phase 1b dose escalation data
select
2025-06-30 (ET)
2025-06-30
16:06:57
I-Mab publishes givastomig monotherapy data in Clinical Cancer Research
select
Sign Up For More Events

News

8.5
07-17Newsfilter
PinnedI-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
4.0
07-09Benzinga
Needham Reiterates Buy on I-MAB, Maintains $5 Price Target
9.0
07-02Newsfilter
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Sign Up For More News

FAQ

arrow icon

What is I-Mab (IMAB) stock price today?

The current price of IMAB is 2.1 USD — it has decreased -2.78 % in the last trading day.

arrow icon

What is I-Mab (IMAB)'s business?

arrow icon

What is the price predicton of IMAB Stock?

arrow icon

What is I-Mab (IMAB)'s revenue for the last quarter?

arrow icon

What is I-Mab (IMAB)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for I-Mab (IMAB)'s fundamentals?

arrow icon

How many employees does I-Mab (IMAB). have?

arrow icon

What is I-Mab (IMAB) market cap?